Anthony T. Reder to Interferon beta-1b
This is a "connection" page, showing publications Anthony T. Reder has written about Interferon beta-1b.
Connection Strength
0.822
-
Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b. Mult Scler. 2019 05; 25(6):837-847.
Score: 0.164
-
The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study. Mult Scler. 2013 Nov; 19(13):1765-72.
Score: 0.116
-
Evidence-based medicine: promise and pitfalls. Mult Scler. 2012 Jul; 18(7):947-8.
Score: 0.109
-
Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Neurology. 2010 Jun 08; 74(23):1877-85.
Score: 0.094
-
Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol. 2002 Aug; 129(1-2):205-15.
Score: 0.055
-
Effects of an anti-IL-10 monoclonal antibody on rIFNbeta-1b-mediated immune modulation. Relevance to multiple sclerosis. J Neuroimmunol. 1998 Jan; 81(1-2):109-15.
Score: 0.040
-
Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis. Pharmacogenomics J. 2013 Oct; 13(5):443-51.
Score: 0.027
-
Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNß-1b trial. Neurology. 2012 Apr 24; 78(17):1315-22.
Score: 0.027
-
Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon ß-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012 Mar; 83(3):282-7.
Score: 0.026
-
Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS. PLoS One. 2011; 6(11):e22444.
Score: 0.026
-
Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry. 2010 Aug; 81(8):907-12.
Score: 0.024
-
Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b. Mult Scler. 2010 Jan; 16(1):30-8.
Score: 0.023
-
Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. Clin Ther. 2009 Aug; 31(8):1724-36.
Score: 0.022
-
Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2007 Mar 27; 68(13):977-84.
Score: 0.019
-
Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology. 2006 Feb 28; 66(4):472-6.
Score: 0.018
-
Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler. 2004 Apr; 10(2):126-38.
Score: 0.015
-
Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest. 1997 Jun 01; 99(11):2664-71.
Score: 0.010
-
Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis. Ann Neurol. 1995 Oct; 38(4):625-32.
Score: 0.009